Boill Healthcare Holdings Limited provided earnings guidance for the year ended 31 March 2019. For the year, the Group is expected to record a consolidated net loss of approximately HKD 220 million for the Period, as compared with the consolidated net loss of approximately HKD 195 million for the year ended 31 March 2018. Such expected substantial consolidated net loss for the Period was mainly due to the following: The revenue of sales of properties has declined by approximately 30% for the Period as compared with the corresponding year ended 31 March 2018 resulting from the weakened demand of potential home buying customers due to deterioration of their overall financial condition brought by the uncertain global macro-economic environment; The revenue of the foundation piling business has dropped more than 60% for the Period as compared with the corresponding year ended 31 March 2018 resulting from the discounts offered for tendered projects involving intense market competition with other subcontractors. However, the other costs (including depreciation and salaries) have not dropped in proportion with the decreased revenue; The construction of the project in Shanghai has not yet been completed and no revenue has been recognized while the cost incurred for daily operation was not less than HKD 14 million for the Period (2018: approximately HKD 5 million); Loss on fair value of approximately HKD 27 million on investment properties under construction were derived for the Period (2018: gain on fair value of approximately HKD 17 million); and No significant gains on disposal of equity investment were derived for the Period (2018: approximately HKD 58 million).